| アイテムタイプ |
デフォルトアイテムタイプ（フル）(1) |
| 公開日 |
2026-09-08 |
| タイトル |
|
|
タイトル |
Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Primary Plasma Cell Leukemia in Japan |
|
言語 |
en |
| 作成者 |
前垣, 雅哉
高橋, 勉
鈴木, 一史
Minakata, Daisuke
Terao, Toshiki
佐竹, 敦志
半下石, 明
Oyake, Tatsuo
神田, 善伸
Aotsuka, Nobuyuki
Tsukada, Nobuhiro
多林, 孝之
Kobayashi, Hikaru
Nawa, Yuichiro
一戸, 辰夫
Ohbiki, Marie
熱田, 由子
河村, 浩二
|
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Primary plasma cell leukemia (pPCL) is a rare and aggressive subtype of plasma cell malignancy. Although hematopoietic stem cell transplantation (HCT), including autologous HCT (auto-HCT) and allogeneic HCT (allo-HCT), is widely used, an optimal treatment strategy is undetermined. We retrospectively analyzed patients with pPCL who underwent HCT between 2006 and 2022 in Japan using Japanese registry data. Overall, 182 patients (117 and 65 who underwent auto-HCT and allo HCT, respectively) were included. Patients in the allo-HCT group were younger, had more advanced disease, and underwent tandem HCT more frequently than did those in the auto-HCT group. There was no statistically significant difference in overall survival (OS) between the groups (P=0.46), with a median OS of 3.2 years (95% CI 2.1–4.3 years) in the auto-HCT group and 1.4 years (95% CI 0.8–3.9 years) in the allo-HCT group. Comparing the four different transplantation strategies (single auto-HCT, single allo-HCT, tandem autologous-autologous HCT, and tandem autologous-allogeneic HCT), the single allo-HCT group had the poorest OS because of early mortality. Tandem autologous-allogeneic HCT appeared to provide better long-term survival. In the multivariate analysis, disease status, Eastern Cooperative Oncology Group Performance Status, and tandem transplantation were significant factors influencing OS. A matched-pair analysis using propensity scores revealed no significant differences in OS between the auto-HCT and allo-HCT groups. However, the allo-HCT group appeared to have better long-term survival than the auto HCT group. Allogeneic transplantation, including tandem autologous-allogeneic-HCT, may offer long-term survival benefits with appropriate patient selection. Further studies are warranted to optimize the transplantation strategies and pre- and post-transplantation treatments for pPCL. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Elsevier |
|
言語 |
en |
| 日付 |
|
|
日付 |
2025-12 |
|
日付タイプ |
Issued |
| 日付 |
|
|
日付 |
2026-12-06 |
|
日付タイプ |
Available |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.jtct.2025.08.026 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
26666367 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
26666375 |
| 書誌情報 |
en : Transplantation and Cellular Therapy
巻 31,
号 12,
p. 1031.e1,
発行日 2025-12
|
| 出版者情報 |
|
|
|
出版者名 |
Elsevier |
|
|
言語 |
en |
| アクセス権 |
|
|
アクセス権 |
embargoed access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_f1cf |
| 権利情報 |
|
|
権利情報 |
© 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. |
|
言語 |
en |
| 権利情報 |
|
|
権利情報Resource |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
権利情報 |
This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
言語 |
en |
Transpl. Cell. Ther.31(12)_1031.e1.pdf (509 KB)
.png)
